Jaguar Health (JAGX) SEC Filings: History & Chart

Jaguar Health, Inc.(JAGX)

Biotechnology · San Francisco, CA

$5.90+1.17 (+24.74%)

Delayed quote: Oct 6, 2026, 12:45 PM EDT

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

San Francisco, CA

47 employees

jaguar.health

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lisa A. Conte

View full financials

Form	Filing Date	Accepted	Document
8-K	Oct 5, 2026	Oct 5, 2026	View filing
PRER14A	Sep 29, 2026	Sep 29, 2026	View filing
8-K	Sep 28, 2026	Sep 28, 2026	View filing
8-K	Sep 25, 2026	Sep 24, 2026	View filing
SC 13G/A	Sep 24, 2026	Sep 24, 2026	View filing
424B5	Sep 24, 2026	Sep 24, 2026	View filing
8-K	Sep 24, 2026	Sep 24, 2026	View filing
8-K	Sep 21, 2026	Sep 21, 2026	View filing
PRE 14A	Sep 18, 2026	Sep 18, 2026	View filing
8-K	Sep 15, 2026	Sep 15, 2026	View filing
8-K	Sep 15, 2026	Sep 15, 2026	View filing
8-K	Sep 4, 2026	Sep 4, 2026	View filing
424B5	Sep 3, 2026	Sep 3, 2026	View filing
424B3	Aug 21, 2026	Aug 21, 2026	View filing
8-K	Aug 19, 2026	Aug 19, 2026	View filing
10-Q	Aug 19, 2026	Aug 19, 2026	View filing
EFFECT	Aug 14, 2026	Aug 17, 2026	View filing
NT 10-Q	Aug 14, 2026	Aug 14, 2026	View filing
POS AM	Aug 11, 2026	Aug 11, 2026	View filing
DEF 14A	Aug 3, 2026	Aug 3, 2026	View filing
424B3	Jul 27, 2026	Jul 27, 2026	View filing
424B3	Jul 27, 2026	Jul 27, 2026	View filing
EFFECT	Jul 24, 2026	Jul 27, 2026	View filing
EFFECT	Jul 24, 2026	Jul 27, 2026	View filing
PRE 14A	Jul 24, 2026	Jul 24, 2026	View filing
S-1/A	Jul 24, 2026	Jul 24, 2026	View filing
S-1	Jul 16, 2026	Jul 15, 2026	View filing
S-1	Jul 16, 2026	Jul 15, 2026	View filing
8-K	Jul 14, 2026	Jul 14, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing

SEC Filings

Recent Filings